Oncology Institute, Inc.
TOINasdaqHealthcare · Services-Offices & Clinics of Doctors of Medicine · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $502.7M | $393.4M | $324.2M | $252.5M | $203.0M | $187.5M |
| Operating income | −$36.1M | −$60.1M | −$77.0M | −$82.0M | −$45.9M | −$8.2M |
| Net income | −$60.6M | −$64.7M | −$83.1M | $152,000 | −$10.9M | −$14.3M |
| Total assets | $164.7M | $172.7M | $209.2M | $261.7M | $203.4M | $65.7M |
| Total liabilities | $180.4M | $169.1M | $152.2M | $138.5M | $99.3M | $37.6M |
| Equity | −$15.7M | $3.6M | $57.0M | $123.2M | $104.2M | $28.1M |
| EPS (diluted) | $-0.54 | $-0.71 | $-0.92 | $-0.21 | $-0.16 | $-0.24 |
| Shares out. | 75.8M | 74.3M | 74.6M | 73.2M | 73.2M | 5.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −7.2%
- Net margin
- −12.1%
- Return on equity
- 385.5%
- Return on assets
- −36.8%
- Return on capital (ROCE)
- −38.5%
- Liabilities / assets
- 109.5%
- Debt / equity
- —
- Book value / share
- $-0.21
- Revenue growth (YoY)
- 27.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -5.27distress
- Accruals / assets
- −21.9%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 18, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- M33 Growth I L.P.Activist (13D)May 15, 2026
- Chernett JoreyPassive (13G)Mar 16, 2026
- Fog Ventures Investments, LlcPassive (13G)Jun 24, 2025
- Sarin Ravi YangActivist (13D)Apr 23, 2025
- Fmr LlcPassive (13G)Dec 6, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6.5M | 3.4 | -11.1% |
| Apr 30, 2026 | 7.3M | 6.0 | -9.2% |
| Apr 15, 2026 | 8.1M | 6.2 | -2.7% |
| Mar 31, 2026 | 8.3M | 3.3 | -7.6% |
| Mar 13, 2026 | 9.0M | 3.9 | -1.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Item 1.05May 22, 2026
- Results of operationsMay 7, 2026
- Regulation FD disclosureMar 13, 2026
- Results of operationsMar 12, 2026
- Director / officer change · Regulation FD disclosureFeb 23, 2026
- Results of operationsJan 12, 2026
- Director / officer change · Regulation FD disclosureJan 7, 2026
- Director / officer change · Regulation FD disclosureDec 1, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4May 22, 2026
- 4May 22, 2026
- 4May 22, 2026
- 8-KFORM 8-KMay 22, 2026
- 4OWNERSHIP DOCUMENTMay 21, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- SCHEDULE 13D/AMay 15, 2026
- 8-KFORM 8-KMay 7, 2026
- 10-QMay 7, 2026
- DEFA14AApr 30, 2026
- DEF 14AApr 30, 2026
- ARSApr 28, 2026
- 4Apr 23, 2026
- 4Apr 23, 2026
- 4Apr 16, 2026
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.